Skip to content
drillr.ai
Sign up

URGN

UroGen Pharma Ltd.

NASDAQ · Healthcare · Biotechnology · US

$28.38
−17.50%
Ask drillr

  • Nov 4, 2026, 16:06 UTC

    UroGen Pharma Ltd. reported a third-quarter loss of $0.03 per share, compared with a loss of $0.69 per share a year earlier.

    Source:

  • Nov 4, 2026, 13:00 UTC

    UroGen Pharma reported that ZUSDURI generated $68.0 million in revenue in the third quarter of 2026, up 35% quarter over quarter.

    Source:

  • Nov 4, 2026, 13:00 UTC

    The FDA accepted UroGen Pharma's NDA for UGN-103 for review and set a PDUFA goal date of June 14, 2027.

    Source:

  • Nov 2, 2026, 13:00 UTC

    UroGen Pharma Ltd. announced that the first patient had been dosed in a Phase 1 trial evaluating UGN-501 for non-muscle invasive bladder cancer.

    Source:

  • Oct 19, 2026, 12:00 UTC

    The U.S. Food and Drug Administration accepted UroGen Pharma Ltd.’s NDA for investigational UGN-103 to treat adults with recurrent LG-IR-NMIBC and set a PDUFA target action date of June 14, 2027.

    Source:

  • Aug 20, 2026, 11:00 UTC

    UroGen Pharma entered into a strategic collaboration and investment agreement with IntraGel to access its biodegradable sustained-release gel platform and expand its oncology pipeline.

    Source:

  • Aug 5, 2026, 00:00 UTC

    UroGen Pharma Ltd. reported its Q2 2026 financial results, with total revenue of $72.5 million and a net loss of $14.4 million.

    Source:

  • Jul 8, 2026, 12:00 UTC

    UroGen Pharma received FDA clearance of its Investigational New Drug application for UGN-501, an investigational oncolytic virus for non-muscle invasive bladder cancer.

    Source: